RU2019131719A - Макроинкапсулированные терапевтические клетки и способы их применения - Google Patents
Макроинкапсулированные терапевтические клетки и способы их применения Download PDFInfo
- Publication number
- RU2019131719A RU2019131719A RU2019131719A RU2019131719A RU2019131719A RU 2019131719 A RU2019131719 A RU 2019131719A RU 2019131719 A RU2019131719 A RU 2019131719A RU 2019131719 A RU2019131719 A RU 2019131719A RU 2019131719 A RU2019131719 A RU 2019131719A
- Authority
- RU
- Russia
- Prior art keywords
- barrier
- macrocapsule
- glucomannan
- sulfate
- composition according
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title claims 2
- 230000004888 barrier function Effects 0.000 claims 17
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims 15
- 229920002581 Glucomannan Polymers 0.000 claims 15
- 229940046240 glucomannan Drugs 0.000 claims 15
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 14
- 239000001913 cellulose Substances 0.000 claims 6
- 229920002678 cellulose Polymers 0.000 claims 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 3
- 235000010413 sodium alginate Nutrition 0.000 claims 3
- 239000000661 sodium alginate Substances 0.000 claims 3
- 229940005550 sodium alginate Drugs 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/04—Alginic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0012—Cell encapsulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
- A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Zoology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Physiology (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
Claims (23)
1. Композиция, содержащая цилиндрическую макрокапсулу, вмещающую множество инсулин-продуцирующих клеток, причем указанная макрокапсула содержит по меньшей мере один барьер, содержащий:
(a) сульфат целлюлозы и глюкоманнан или сульфат глюкоманнана; или
(b) альгинат натрия;
и второй барьер, не содержащий глюкоманнан или сульфат глюкоманнана; где цилиндрическая макрокапсула имеет диаметр по меньшей мере 1,5 мм.
2. Композиция по п. 1, где макрокапсула имеет длину по меньшей мере приблизительно 11 см.
3. Композиция по п. 1 или 2, где макрокапсула содержит по меньшей мере приблизительно 50000 клеток на см.
4. Композиция, содержащая цилиндрическую макрокапсулу, вмещающую множество инсулин-продуцирующих клеток, где макрокапсула содержит по меньшей мере первый барьер и второй барьер, где первый барьер заключен во втором барьере, и где макрокапсула имеет диаметр по меньшей мере 1,5 мм.
5. Композиция по п. 4, где диаметр макрокапсулы составляет по меньшей мере 2,0 мм.
6. Композиция по п. 4 или 5, где второй барьер содержит сульфат целлюлозы и глюкоманнан или сульфат глюкоманнана.
7. Композиция по любому из пп. 4-6, где как первый, так и второй барьер содержат сульфат целлюлозы и сульфат глюкоманнана.
8. Композиция по п. 4 или 5, где второй барьер не содержит глюкоманнан или сульфат глюкоманнана.
9. Композиция по любому из пп. 4-6, где первый барьер содержит альгинат натрия.
10. Композиция по любому из пп. 4-9, где макрокапсула имеет длину по меньшей мере приблизительно 11 см.
11. Композиция по любому из пп. 4-10, где макрокапсула содержит по меньшей мере приблизительно 50000 клеток на см.
12. Композиция, содержащая макрокапсулу, вмещающую множество терапевтических клеток, где макрокапсула имеет цилиндрическую форму и диаметр по меньшей мере 1,5 мм, причем макрокапсула содержит по меньшей мере первый барьер и второй барьер, где первый барьер заключен во второй барьер, где первый барьер содержит:
(a) сульфат целлюлозы и глюкоманнан или сульфат глюкоманнана; или
(b) альгинат натрия,
и где второй барьер необязательно содержит сульфат целлюлозы и глюкоманнан или сульфат глюкоманнана; или второй барьер не содержит сульфат целлюлозы и глюкоманнан или сульфат глюкоманнана.
13. Композиция по п. 12, где макрокапсула содержит по меньшей мере приблизительно 50000 клеток на см.
14. Способ лечения диабета у нуждающегося в этом субъекта, включающий имплантацию субъекту, страдающему диабетом, композиции по любому из пп. 1-13.
15. Способ по п. 14,
(a) где субъект является взрослым; или где субъект является ребенком; и/или
(b) где субъект страдает диабетом I типа; или где субъект страдает диабетом II типа.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482413P | 2017-04-06 | 2017-04-06 | |
| US62/482,413 | 2017-04-06 | ||
| PCT/US2018/020446 WO2018186953A1 (en) | 2017-04-06 | 2018-03-01 | Macro-encapsulated therapeutic cells and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2019131719A true RU2019131719A (ru) | 2021-05-06 |
Family
ID=61764135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019131719A RU2019131719A (ru) | 2017-04-06 | 2018-03-01 | Макроинкапсулированные терапевтические клетки и способы их применения |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11975031B2 (ru) |
| EP (1) | EP3606613A1 (ru) |
| JP (1) | JP7293126B2 (ru) |
| KR (1) | KR102572188B1 (ru) |
| CN (1) | CN110709137A (ru) |
| AU (1) | AU2018250008B2 (ru) |
| BR (1) | BR112019020611A2 (ru) |
| CA (1) | CA3058369A1 (ru) |
| IL (1) | IL269817B2 (ru) |
| RU (1) | RU2019131719A (ru) |
| SG (1) | SG11201909206XA (ru) |
| WO (1) | WO2018186953A1 (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202008267TA (en) * | 2018-03-01 | 2020-09-29 | Seraxis Inc | Macro-encapsulated therapeutic cells, devices, and methods of using the same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4743545A (en) * | 1984-08-09 | 1988-05-10 | Torobin Leonard B | Hollow porous microspheres containing biocatalyst |
| US5545423A (en) * | 1991-11-25 | 1996-08-13 | Vivorx, Inc. | Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials |
| US5334640A (en) * | 1992-04-08 | 1994-08-02 | Clover Consolidated, Ltd. | Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods |
| CZ122795A3 (en) * | 1992-11-16 | 1996-02-14 | Univ Brown Res Found | Implantable selectively permeable macroscopic case and process for producing thereof |
| BR0315130A (pt) * | 2002-10-11 | 2005-08-16 | Novocell Inc | Composições para terapia celular, terapeuticamente efetivas e de encapsulamento de material biológico, respectivos método e uso |
| US20070237749A1 (en) | 2006-04-07 | 2007-10-11 | Wang Taylor G | Multi-membrane immunoisolation system for cellular transplant |
| US20080292690A1 (en) * | 2006-04-07 | 2008-11-27 | Technology Center | Multi-membrane immunoisolation system for cellular transplant |
| US9540630B2 (en) * | 2008-09-17 | 2017-01-10 | Beta O2 Technologies Ltd. | Optimization of alginate encapsulation of islets for transplantation |
| KR101096902B1 (ko) * | 2009-01-15 | 2011-12-22 | 가톨릭대학교 산학협력단 | 당뇨병 치료용 알기네이트-키토산 이중막의 췌도 미세캡슐 및 이의 제조방법 |
| WO2012130567A1 (en) * | 2011-03-29 | 2012-10-04 | Beta-Cell Nv | Method for encapsulated therapeutic products and uses thereof |
| KR101373518B1 (ko) * | 2011-04-28 | 2014-03-13 | 서울대학교산학협력단 | 췌도 캡슐 및 이의 제조 방법 |
| BR112016010191A2 (pt) * | 2013-11-07 | 2017-08-08 | Massachusetts Gen Hospital | matriz de eluição e usos desta |
| US9408807B2 (en) * | 2015-01-13 | 2016-08-09 | Taylor Gun-Jin Wang | Semi-permeable encapsulation system with tapered conduits for diabetes reversal |
| WO2016187225A1 (en) * | 2015-05-17 | 2016-11-24 | Massachusetts Institute Of Technology | Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates |
-
2018
- 2018-03-01 CA CA3058369A patent/CA3058369A1/en active Pending
- 2018-03-01 CN CN201880036340.6A patent/CN110709137A/zh active Pending
- 2018-03-01 KR KR1020197030643A patent/KR102572188B1/ko active IP Right Grant
- 2018-03-01 IL IL269817A patent/IL269817B2/en unknown
- 2018-03-01 RU RU2019131719A patent/RU2019131719A/ru not_active Application Discontinuation
- 2018-03-01 AU AU2018250008A patent/AU2018250008B2/en active Active
- 2018-03-01 WO PCT/US2018/020446 patent/WO2018186953A1/en unknown
- 2018-03-01 JP JP2019554669A patent/JP7293126B2/ja active Active
- 2018-03-01 US US15/909,449 patent/US11975031B2/en active Active
- 2018-03-01 EP EP18713086.9A patent/EP3606613A1/en active Pending
- 2018-03-01 BR BR112019020611A patent/BR112019020611A2/pt not_active Application Discontinuation
- 2018-03-01 SG SG11201909206X patent/SG11201909206XA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018186953A1 (en) | 2018-10-11 |
| EP3606613A1 (en) | 2020-02-12 |
| IL269817B2 (en) | 2024-07-01 |
| AU2018250008A1 (en) | 2019-10-31 |
| KR102572188B1 (ko) | 2023-08-30 |
| CN110709137A (zh) | 2020-01-17 |
| IL269817B1 (en) | 2024-03-01 |
| IL269817A (en) | 2019-11-28 |
| KR20190133708A (ko) | 2019-12-03 |
| US11975031B2 (en) | 2024-05-07 |
| BR112019020611A2 (pt) | 2020-04-22 |
| SG11201909206XA (en) | 2019-11-28 |
| AU2018250008B2 (en) | 2024-05-02 |
| CA3058369A1 (en) | 2018-10-11 |
| US20180289746A1 (en) | 2018-10-11 |
| JP2020512999A (ja) | 2020-04-30 |
| JP7293126B2 (ja) | 2023-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | Advances in the application of electrospun drug-loaded nanofibers in the treatment of oral ulcers | |
| JP2017080618A5 (ru) | ||
| HRP20151444T4 (hr) | Sredstva za liječenje i postupci liječenja dlbcl | |
| GB2523863A8 (en) | Imageable polymers | |
| MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| Suchánek et al. | Hyaluronic acid-based medical device for treatment of alveolar osteitis—clinical study | |
| BR112017000813A2 (pt) | partículas de microgel de autorrecozimento controláveis para aplicações biomédicas | |
| AR088458A1 (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y fingolimod | |
| JP2016518458A5 (ru) | ||
| HRP20240798T1 (hr) | Terapija matičnim stanicama kod patologija endometrija | |
| BR112021017878A2 (pt) | Carbonato de magnésio com superfície reagida, sistema de liberação, formulação de cuidados domiciliares, métodos para preparar um carbonato de magnésio com superfície reagida e para preparar um sistema de liberação, e, uso de um carbonato de magnésio com superfície reagida e de um sistema de liberação | |
| RU2019131719A (ru) | Макроинкапсулированные терапевтические клетки и способы их применения | |
| RU2015143475A (ru) | Продукт и способ лечения диареи | |
| BR112018010066A2 (pt) | agente estimulante do receptor 5-hidroxitriptamina 1b para intensificar potencial de enxerto in vivo | |
| BR112018010016A2 (pt) | emulsão pickering, composição para cuidados com a pele, e, processo para produção de uma emulsão pickering. | |
| RU2016119132A (ru) | Способы лечения патологических состояний глаза с помощью имплантата с долговременной доставкой лекарственного вещества | |
| BR112017012289A2 (pt) | agente para injeção hipodérmica | |
| Blakney et al. | In vitro–ex vivo correlations between a cell-laden hydrogel and mucosal tissue for screening composite delivery systems | |
| EA202191063A1 (ru) | Новая дозированная форма | |
| DE602004006768D1 (de) | Aus mit gamma-strahlen bestrahltem pektin hergestellte pektinfilme | |
| RU2018107515A (ru) | Средство, снижающее интенсивность гиперактивности детрузора с нарушенной сократимостью | |
| BR112018008769A2 (pt) | formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída | |
| Perkins | Teen’s cancer research scores big at Intel ISEF competition | |
| Reilly | Ask the doctor. I'm in my late 70s and have been getting about four cortisone shots a year for the past several years for the arthritis in my left knee. They really help with the pain, but I've heard that long-term, there could be bad side effects. Should I be worried? | |
| Garcia-Marcos | Wheezing in infants: A pandemic condition that need to be treated with patience |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20210302 |